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A B S T R A C T
Evidence is accumulating which may result in plasma free metadrenalines (PMets) becoming the preferred test
for diagnosing phaeochromocytoma and paraganglioma. Moreover, increased availability and benefits over
other analytical methods like liquid chromatography with electrochemical detection and immunoassay are
causing liquid chromatography tandem mass spectrometry (LC-MS/MS) to become the method of choice for
PMet measurement. This review explores the evidence-base supporting this, and summarises published LC-MS/
MS analytical methods for PMet analysis. Key aspects of methods (including SPE extraction, HILIC chromato-
graphy, MRM MS-detection and standardisation) are discussed. Common causes of analytical interference (e.g.
ion suppression/enhancement, ionic cross talk, in source transformation and isobaric interferences) are outlined
to illustrate the importance of sample purification and chromatographic resolution. The importance of supine,
fasting sampling and Bayesian interpretation against supine, fasting reference intervals are explained, as well as
the importance of age-specific reference intervals for normetadrenaline. Confounding factors like diet, drugs,
renal function and acute illness are explored, along with potential strategies to address these (e.g. CKD-specific
reference intervals).
1. Introduction
Clinical practice guidelines [1] currently advocate with high-level
evidence that total fractionated urine metadrenalines (UMets) or
plasma free metadrenalines (PMets) should be used in the initial bio-
chemical screening for phaeochromocytomas and paragangliomas
(PPGL), with no preference expressed for either test. In addition, UMets
and PMets are both suggested for biochemical monitoring of recurrent
or metastatic disease [1]. Metadrenaline (MA, synonym metanephrine),
normetadrenaline (NMA, synonym normetanephrine) and 3-methox-
ytyramine (3MT) are, respectively, O-methylated metabolites of the
catecholamines adrenaline (synonym epinephrine), noradrenaline
(synonym norepinephrine) and dopamine. Total urine metadrenalines
refers to measurement of both free and conjugated metadrenalines
(synonym metanephrines), with acid hydrolysis or enzymatic decon-
jugation being used to liberate free metadrenalines from their sulphate-
conjugated metabolites. The term metadrenalines often relates to MA
and NMA only. Separate measurement of MA and NMA is termed
“fractionated”. Only the unconjugated (free) metadrenalines are mea-
sured in plasma [2]. Evidence is accumulating that urinary free meta-
bolites (without deconjugation by acid hydrolysis) may confer ad-
vantages over UMets and that PMets offers superior diagnostic
performance over urinary metabolites in high-risk patients with ap-
propriate pre-analytical precautions [3]. Differences in diagnostic
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performance between plasma and urine were not evident in patients
with low pretest prevalence [3]. Superior performance of PMets (sam-
pled in the supine position) over UMets which disappears in low-risk
patients is corroborated [4]. Further advantages and disadvantages of
PMets compared with UMets are listed in Table 1 (adapted from [5]).
PMets may become the preferred test in future guidelines with pre-
ference shifting to urinary tests when accurate plasma methods, ap-
propriate reference intervals, or adherence to pre-analytical blood
sampling precautions cannot be achieved [3]. The diagnostic perfor-
mance (sensitivity and specificity) of published PMet and UMet
methods have been reviewed elsewhere [4,5]. Clinical practice guide-
lines [1] and a recent systematic review [4] both recommend mea-
suring PMets by liquid chromatography tandem mass spectrometry (LC-
MS/MS) or liquid chromatography with electrochemical detection (LC-
ECD) in supine samples to provide biochemical evidence of PPGL. Im-
munoassay (IA) methods have been published but suffer from lower
diagnostic sensitivity, imprecision, negative bias for MA and NMA and
false-negative (FN) results compared with other methods [1]. More-
over, 3MT measurement is generally not possible by IA and stereo-
specificity is an issue [6,7]. Measurement of PMets is challenging due to
low physiological concentrations, hydrophilic properties, complexity of
the matrix and lack of unique chemical characteristics. This review
aims at summarising published LC-MS/MS methods for measurement of
PMets. Historical methods have previously been reviewed [8], as have
ECD and urine methods [9].
2. LC-MS/MS analytical methods
LC-MS/MS is regarded as the “gold-standard” method [1] and is the
method of choice, as reflected by its predominance in international
quality assurance programs [3]. Table 2 summarises the relative ad-
vantages and disadvantages of LC-MS/MS methods for PMets compared
to LC-ECD and IA methods (adapted from [10]). Another benefit of LC-
MS/MS methods is the ability to accurately and precisely measure 3MT.
The majority of PPGL give rise to increased NMA (either alone or in
combination with increases in other PMets) [10]. However, there are
some dopaminergic tumours that can only be detected through solitary
increased 3MT [11]. These are associated with gene mutations en-
coding succinate dehydrogenase subunits or metastatic disease
[12–14]. 3MT measurement is useful for detecting these tumours and
has the greatest clinical utility in the evaluation of metastatic disease.
High analytical sensitivity is required for 3MT measurement owing to
upper limits of reference intervals (ULRI)< 100 pmol/L [10]. Studies
have shown that combined plasma free NMA, MA and 3MT detected
more biochemically active head and neck paragangliomas than 24 h
urinary deconjugated NMA, MA and 3MT [15]. Moreover, that urinary
3MT has limited utility for screening dopamine-producing PPGLs [16]
and plasma free 3MT is superior to urinary free and deconjugated 3MT
for assessing tumoural dopamine production [3].
LC-MS/MS methods comprise extraction of the metadrenalines from
the complex plasma matrix, followed by chromatography, and mass
spectrometric detection. Table 3 summarises the key analytical and
performance characteristics of in-house LC-MS/MS methods for PMets.
It is important to note that performance characteristics e.g. precision
and lower limit of the measuring intervals (LLMI) were variably defined
and may not be equivalent but have been presented as stated in the
publication. Recent guidance on clinical method validation [17] should
reduce this variability in future. An earlier method which required pre-
concentration has not been included [18], and neither have gas chro-
matography mass spectrometry methods which are not practicable or
high enough throughput for routine analysis.
2.1. Extraction
The polar and hydrophilic nature of metadrenalines (Fig. 1) com-
plicates their extraction. Solid-phase extraction (SPE) is the most pop-
ular sample preparation technique to minimise matrix effects from
endogenous plasma constituents like phospholipids, salts, and proteins
that can cause ion suppression. The majority of methods employ weak
cation exchange (WCX) [19–25]. The basic nature of metadrenalines
(pKa values in Fig. 1) permits isolation by cation-exchange. The qua-
ternary amine group makes strong cation exchange unsuitable. WCX
binds strong bases using a carbonyl ion-exchanger at pH > 5, allowing
washing with water and acetonitrile (ACN) without elution of meta-
drenalines. An acidic mobile phase is then used for elution [19]. A
minority of methods use mixed mode cation exchange (MCX) [26–28],
which exploit reverse-phase interactions and a sulphonic acid strong
cation exchange for biogenic amine retention [26]. Ion-pairing reagents
may be required for this [27]. Other extraction techniques involve
mixed mode (hydrophilic–lipophilic balance, HLB) [29] or isopropanol
protein precipitation [30]. Sample volume requirement is highly vari-
able (100–1000 μL). The majority of methods involved off-line extrac-
tion, with some on-line extractions described [19,25,27] (not all of
these are still supported). On-line extraction requires capital invest-
ment, but gives simpler and less labour-intensive sample preparation so
is preferable to complex manual SPE if available.
2.2. Chromatography
Hydrophilic interaction liquid chromatography (HILIC) is the most
common chromatographic approach used for measurement of PMets.
HILIC allows polar analytes to be separated on polar stationary phases
(like silica or cyano) using highly organic mobile phase (often ACN)
with relatively low back pressures. It is thought that separation occurs
through partitioning of the analyte of interest between the bulk organic
mobile phase and a partially immobilised layer on that stationary phase
surface that is enriched with water. Additional mechanisms are possible
too [31]. Buffers containing ammonium formate (AmF) help to stabilise
charge on both the analytes and the stationary phase. HILIC also offers
enhanced sensitivity in electrospray ionisation (ESI) methods owing to
efficient desolvation in the highly organic mobile phase at which elu-
tion occurs [31]. However, HILIC columns are unable to chromato-
graphically resolve metadrenalines [19,20,22,24–26,30], with the po-
tential for analytical interference (see Section 3.2). Amide HILIC
columns retain the advantages of HILIC with greater chromatographic
separation [10]. Reverse phase columns have also been utilised for
enhanced chromatographic resolution including Hypercarb porous
graphite column (PGC) with ion-pairing reagents [27], Acquity UPLC
Table 1
Summary of the advantages and disadvantages of PMets compared with UMets. Adapted from [5].
Advantages PMets vs UMets Reflect the free metadrenalines produced directly by tumours.
Samples are more convenient and reliable for patients to collect than 24 h urines.
Dietary and drug confounders are easier to control than in urine.
More useful in chronic kidney disease (CKD).
Disadvantages PMets vs UMets Requirement for supine/fasted samples.
Greater analytical challenges (picomolar concentrations in a complex matrix necessitating extraction).
Sample instability (collected on ice, with prompt centrifugation and freezing).
Increased cost of clinic sampling.
Abbreviations: PMets - plasma free metadrenalines; UMets - total fractionated urine metadrenalines.
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HSS T3 [28] and C18 [23]. Other analytical columns include LUNA
Cyano which exploit dipole interactions [29] and pentafluorophenyl
(PFP) which can utilise dipole, π-π, and shape interactions facilitated by
the halogenated stationary phase [21].
2.3. Detection
Positive ionisation mode is used for PMet analysis since these polar
compounds exist as positively charged amines in solution. The majority
of methods [19–28,30] utilise ESI for optimal signal strength [10] with
some examples of atmospheric pressure chemical ionisation (APCI)
[29]. NMA, MA, and 3MT (molecular masses 183, 197, and 167, re-
spectively) are protonated in positive ion mode to give molecular ions
with m/z 184 (NMA), 198 (MA) and 168 (3MT). As illustrated in Fig. 2,
the protonated molecular ions for NMA and MA undergo spontaneous
loss of water to yield precursor ion fragments with m/z 166 (NMA) and
180 (MA). Characteristic product ions are formed by collision-induced
dissociation with further loss of a protonated methoxy group in the
collision cell to fragments of m/z 134 (NMA) and 148 (MA). These
transitions are more specific than water loss transitions, and the use of
multiple reaction monitoring (MRM) pairs increases specificity [29]. In
MRM mode, the majority of methods use 166→ 134 (NMA) and 180→
148 (MA) transitions for quantification [19–22,24–27,29,30]. As shown
in Fig. 3, facile loss of ammonia from the protonated molecular ion of
3MT yields a precursor ion of m/z 151 [10,20,28], with a characteristic
product ion of 119. Thus, the majority of methods use the 151→ 119
transition for quantification of 3MT [19,25,28]. This transition should
be investigated for ionic cross talk [32]. Qualifier ions are used for
enhanced specificity in detection. Qualifier transitions for NMA in-
cluded 166→ 106 [24,28] and 166→ 121 [22]. Qualifier transitions for
MA included 180→ 165 [24], 180→ 148 [28] and 180→ 120 [22],
with some methods using the 180→ 165 transition for quantification
[23,28]. Qualifier transitions for 3MT were 151→ 91 [19,28], with
some methods using this as the transition for quantification [20].
2.4. Standardisation
Cerilliant certified reference material in solvent is available for
NMA and MA (Catecholamine Mix 2) and 3MT. However, higher-order
reference material in human plasma or reference measurement methods
are not available for PMets [33]. These would be required for stan-
dardisation and full comparability between methods. However, com-
mercial suppliers have started to produce PMet kits. One is the Recipe
ClinMass® Complete Kit for Free Metanephrines in Plasma (Recipe
Chemicals+ Instruments GmbH, Munich, Germany; MS11000, March
2019). This meets the regulatory requirements to be certified a Con-
formité Européenne In Vitro Diagnostic (CE-IVD) medical device. It
comprises simple sample preparation (protein precipitation), on-line
SPE and isotope-labelled internal standardisation. An alternative Recipe
ClinMass® complete kit with manual sample preparation for standard
LC-MS/MS systems is also available (MS11100, March 2019). NMA, MA
and 3MT exhibit similar retention times in this method which has po-
tential interference implications (as discussed in Section 3.2). Chrom-
systems also have multiple options for MassChrom® Free Metanephrines
in Plasma. One uses manual sample preparation on sample clean up
columns (Chromsystems Instruments & Chemicals GmbH, Munich,
Germany; 81000/C, March 2019) and another uses 96 SPE Well Plates
(81000, March 2019) with either manual or automated sample pre-
paration. Centrifugation is used to pass solvents through the SPE. These
are CE-IVD validated kits which promise straightforward sample pre-
paration, isotopically labelled internal standardisation and importantly
from an interference perspective, chromatographic resolution is
achieved for all PMets. Cost is one of the disadvantages of these kits but
advantages include traceability and decreased staff requirements for
verification and sample preparation. Moreover, there are two com-
mercial sources of calibrators (Chromsystems 6PLUS1® Multilevel
Plasma Calibrator Set Free Metanephrines, 81039; Recipe ClinCal®
lyophilised Serum Calibrator Set for Metanephrines (Level 0–4),
MS11013; both March 2019) and quality control materials (Chrom-
systems MassCheck® Free Metanephrines Plasma Controls, 0384-0386;
Recipe ClinChek® lyophilised Serum Controls for Metanephrine,
MS11083; both March 2019). This decreases reliance on in-house
Table 2
Summary of the advantages and disadvantages of LC-MS/MS, LC-ECD and IA methods for PMets. Adapted from [10].
LC-MS/MS LC-ECD IA
Advantages Minimal consumable costs. Minimal consumable costs (in-house
methods).
More moderate capital cost of
instrumentation.
Minimal instrumentation costs.
High sample throughput (facilitated by less stringent
requirements for chromatographic separation).
Relatively simple operation and
troubleshooting (expertise implications).
Easy to set up kit methods.
Simplified sample preparation. Some kit methods available with high
consumable costs.
Minimal operator expertise required.
High analytical sensitivity. Moderate analytical sensitivity.
High analytical specificity with fewer interferences. Chromatographic interferences can be
identified.
Precise measurement of 3MT. 3MT measurement possible.
High versatility of LC-MS/MS instruments.
Kit methods and commercial calibrators / quality
control materials available. Some of these are on-line.
Disadvantages High capital cost of instrumentation. Labour-intensive sample preparation. High costs of consumables for kit methods.
Operator expertise required. Susceptible to analytical interferences. Lengthy sample preparation / analysis times.
Some laboratories need to develop in-house methods. Low sample throughput (long sample run
times).
Requires separate measurement of each metabolite.
High cost of kit methods. Interferences difficult to identify.
Poor accuracy with negative bias and potential for false
negatives.
Poor analytical sensitivity.
3-MT measurement not possible (with implications for
dopamine producing tumours, hereditary and metastatic
disease).
Abbreviations: IA - immunoassay; LC-ECD - liquid chromatography with electrochemical detection; LC- MS/MS - liquid chromatography tandem mass spectrometry;
PMets - plasma free metadrenalines; 3MT- 3-methoxytyramine.
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material and in combination with inter-laboratory quality assurance
programmes facilitates inter-laboratory harmonisation [10,34]. This is
important due to difficulties of making in-house matched calibrators
owing to the ubiquitous presence of metadrenalines in spiked plasma.
3. Analytical considerations for interpreting results
3.1. Reference intervals
False-positive (FP) results are a significant issue for PMet testing,
and sampling conditions like sampling from a seated position, medi-
cation and dietary factors are a notable contribution to these [35].
Clinical practice guidelines advocate collecting PMet samples after
30min of supine rest and establishing reference intervals under the
same conditions to avoid FPs in samples from a seated position inter-
preted against reference intervals from a supine position (lower diag-
nostic specificity) as well as the FNs associated with samples from a
seated position interpreted against reference intervals from a seated
position (lower diagnostic sensitivity) [1]. Upright posture is a powerful
stimulus for the sympathetic nervous system activation and, thus, in-
creases plasma noradrenaline and NMA concentrations [1,10]. Conse-
quently, seated reference intervals are higher than the equivalent su-
pine reference intervals [1]. Significant posture-associated changes are
not observed in patients with PPGL [1]. Sampling from the seated po-
sition decreases diagnostic accuracy of LC-MS/MS methods, negates the
benefits compared with urinary fractionated metadrenalines and may
necessitate alternative urine testing [10]. When samples are collected
from a seated position for ease, repeat sampling from a supine position
is recommended to exclude FP results [1]. There benefits of supine over
seated PMet sampling on diagnostic accuracy have been demonstrated
in more recent studies [4,35–39]. Other studies have concluded ac-
ceptable diagnostic performance for PMets collected from a seated
position interpreted against reference intervals from a seated position
[40] or against supine, fasted reference intervals [41]. Although not
extensively studied, diurnal variability does not appear to be a sig-
nificant factor, thereby allowing sampling at any time of the day [42].
Owing to the clinical implications of a missed diagnosis, the ULRI
for PMets must be optimised for diagnostic sensitivity and negative
predictive value. Laboratories should also establish or verify their own
reference values before routine use [43]. Negative results reliably ex-
clude PPGL in the majority of cases, but all positive results require
follow-up. Follow-up should be guided by the clinical presentation, pre-
test probability, as well as the magnitude and pattern of the elevation
above the ULRI [1]. FPs are less likely if NMA and MA are elevated, and
results are highly suggestive of PPGL if either NMA or MA are elevated
at least 3-fold relative to the ULRI [1]. ULRI thresholds of 2-fold [43]
and 3.5- to 4-fold [44] have also been used in other publications. This
Bayesian approach differs from the conventional binary interpretation
against clinical chemistry reference intervals. Further assurance can be
provided by demonstrating similar metadrenaline patterns in paired
plasma and urine samples [5]. In these cases imaging must be used to
locate the tumour. Plasma NMA and MA can also help to predict tumour
size (strong positive relationship with tumour diameter) and location
(higher concentrations of MA to NMA in adrenal tumours) [44]. In-
creased 3MT has also been associated with dopamine-secreting extra-
adrenal tumours [14].
Borderline results (1–3 x ULRI) are more difficult to interpret in
patient populations with a low pre-test prevalence, particularly owing
to sub-optimal diagnostic specificity [1,5]. These results are not always
followed-up appropriately and carefully selected interpretive comments
may be helpful [45]. In these cases, pre-analytical factors that con-
tribute to FP results should be considered since FP cases exceed true-
positive cases [46]. It may be useful for confirmatory testing after ex-
clusion of sampling position, pharmacological, dietary, and other
causes of FPs.
When plasma NMA is elevated and clinical suspicion is moderate/Ta
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high, the clonidine suppression test measuring plasma NMA can help to
distinguish true-positive results from FPs [1,43]. Others studies suggest
follow-up of positive PMet results by measurement of chromogranin
and urinary fractionated metadrenalines [47]. Where there is a low
clinical probability of PPGL and borderline positive results, biochemical
monitoring after at least 6 months for sustained or more marked ele-
vations in PMets may suggest increased likelihood of a small/enlarging
tumour [1].
Plasma NMA concentrations significantly increased with age,
whereas weaker positive relationships were observed for plasma MA
and 3MT. In the absence of age-specific reference intervals FP NMA
results were significantly greater in patients over 60 years old compared
with patients under 45 years old. Age was found to be an important
contributor to FP PMet results and diagnostic test performance was
improved through use of age-specific reference intervals for NMA and
optimised slightly above 99.5 percentiles for MA and 3MT [48]. The
applicability of these reference intervals to different LC-MS/MS
methods in other laboratories can, in part, be determined from bias
observed in inter-laboratory quality assurance programs [7]. Combined
with a common certified reference material harmonisation of reference
intervals may then be possible [48]. Plasma MA and 3MT concentra-
tions were significantly higher in males than in females but sex-specific
reference intervals are not required in plasma [48]. This corroborates
earlier studies that advocated age-adjusted reference intervals for
plasma NMA [49].
3.2. LC-MS/MS interference
Sample purification and chromatographic separation are important
for selectivity and specificity, even with LC-MS/MS methods for PMets
[10]. Ion suppression or enhancement, ionic cross talk, in source
transformation and isobaric interferences can all cause analytical in-
terference in LC-MS/MS measurement of PMets [10].
When alternative matrices are used (e.g. for in-house calibrators)
differential ion suppression / enhancement between the analyte and its
deuterated internal standard should be investigated to ensure quanti-
fication is not affected [50]. Ion suppression of the analyte and/or in-
ternal standard may occur but have negligible impact on quantification
e.g. cimetidine, ephedrine, labetalol, and pseudoephedrine [22].
Product ion cross talk is an important cause of 3MT over-estimation
that occurs when two different precursor ions give rise to a product ion
with the same m/z that are not chromatographically resolved. 3-O-
Methyldopa is endogenously produced by catechol-O-methyltransferase
action on the dopamine precursor L-dopa and is present at much higher
concentrations than 3MT. Interference in 3MT measurement is parti-
cularly significant in patients with higher 3-O-Methyldopa concentra-
tions e.g. renal insufficiency or L-dopa treatment for Parkinson's dis-
ease. It is attributable to in-source decarboxylation of 3-O-Methyldopa
(relative molecular mass 211.1) to produce a co-eluting fragment with
m/z 151.1 i.e. the same as the precursor ion for 3MT [51] (Fig. 4).
Another example is ionic cross talk between MA and 3MT and is caused
by in-source fragmentation of MA to produce ions mimicking 3MT,
possibly by loss of methyl or hydroxyl groups to form 3MT precursor
ions. The higher concentrations of MA relative to 3MT results in 3MT
over-estimation in any method where NMA, MA and 3MT are not
chromatographically resolved e.g. HILIC methods [32]. Interference of
both 3-O-Methyldopa and MA in 3MT measurement can be eliminated
by chromatographic separation [32,51].
NMA MA 3MT
9.99
9.06
14.22
10.05
9.25
14.21
10.39
9.64
Fig. 1. Structure of NMA, MA and 3MT at pH 3.0,
including all pKa values. Adapted from [79]. Ab-
breviations: MA - metadrenaline; NMA - normeta-
drenaline; 3MT - 3-methoxytyramine.
H2O loss HOCH3 loss
+ ESI ionisation
Precursor ion 
selection
[M – H2O + H+]
m/z = 166
Fragmentation
Product ion 
selection
[M – H2O – HOCH3 + H+]
m/z = 134
H2O loss HOCH3 loss
+ ESI ionisation
Precursor ion 
selection
[M – H2O + H+]
m/z = 180
Fragmentation
Product ion 
selection
[M – H2O – HOCH3 + H+]
m/z = 148
NMA
MA
Fig. 2. Characteristic ionisation and fragmentation of NMA and MA used for quantification in LC-MS/MS methods for PMets. Adapted from [10]. Abbreviations: ESI -
electrospray ionisation; LC- MS/MS - liquid chromatography tandem mass spectrometry; MA - metadrenaline; NMA - normetadrenaline; PMets - plasma free me-
tadrenalines.
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Adrenaline and NMA are isomers and, thus, are subject to isobaric
interference in LC-MS/MS methods unless chromatographic separation
is achieved [10]. Owing to different fragmentation mechanisms, dif-
ferent product ions are observed for adrenaline (m/z 107) and NMA (m/
z 134) which can help distinguish between them [10,29].
For enhanced analytical selectivity for PMets, one study advocates
using multistage fragmentation (MRM3), which can be achieved on
quadrupole-ion trap tandem mass spectrometers. Collision-induced
dissociation produces primary fragment ions which are isolated and
fragmented further to produce secondary fragment ions for quantifi-
cation. MRM3 for NMA and MA on a HILIC column allowed for removal
of co-eluting interferences present in MRM which prevented quantita-
tion by MRM. In MRM mode the transitions used were m/z 166→ 134
(NMA quantifier), 166→ 106 (NMA qualifier), 169→ 137 (D3-NMA),
180→ 148 (MA quantifier), 180→ 165 (MA qualifier) and 183→ 151
(D3-MA). MRM3 transitions were m/z 166→ 134→ 79 (NMA quanti-
fier), 166→ 134→ 116 (NMA qualifier), 180→ 149→ 121 (MA quan-
tifier) and 180→ 149→ 107 (MA qualifier). The MRM3 method was
less sensitive and more imprecise than MRM but still deemed sufficient
for clinical use [24]. Quantifier:qualifier ratios allow co-chromato-
graphing interferences to be identified. However, MRM3 cannot remove
interference from in-source transformation yielding identical products.
Chromatographic resolution is required to remove this interference
[10,51].
3.3. Drugs
As summarised in Table 4, there are numerous drugs that can cause
FP PMet results by LC-MS/MS, both by pharmaco-physiological or
analytical mechanisms. As such, medication-induced FP results should
be excluded when positive PMet results are obtained e.g. by modifying
interfering medication and re-testing [5,52]. However, LC-MS/MS is
less susceptible to analytical interference than high pressure liquid
chromatography with electrochemical detection [43].
Phenoxybenzamine is a nonspecific α-adrenoceptor blocker used in
phaeochromocytoma treatment. Mechanisms for increasing NMA in-
clude decreased α2-adrenoceptor-mediated feedback inhibition of nor-
adrenaline release, potentially with sympathetic activation in reflexive
response. This is a significant cause of FP NMA results and should be
avoided during biochemical testing if possible [52].
Tricyclic and other antidepressants can block sympathoneuronal
uptake of noradrenaline, thereby causing a significant number of FP
NMA results [52]. Other mechanisms by which drugs cause FP NMA
results include altered clearance mechanisms or increased noradrena-
line release by sympathetic nerves [10].
By blocking the metabolism of all O-methylated metabolites,
monoamine oxidase inhibitors vastly increase metadrenalines and
should, therefore, be withdrawn before PMet testing. For most drugs,
withdrawal is only required when positive results are encountered.
[10].
NH3 loss
+ ESI ionisation
Precursor ion 
selection
[M – NH3 + H+]
m/z = 151
Fragmentation
Product ion 
selection
m/z = 119
3MT
Fig. 3. Characteristic ionisation and fragmentation of 3MT used for quantification in LC-MS/MS methods for PMets. Adapted from [10]. 3MT product ions inferred
from [80]. Abbreviations: ESI - electrospray ionisation; LC- MS/MS - liquid chromatography tandem mass spectrometry; PMets - plasma free metadrenalines; 3MT - 3-
methoxytyramine.
NH3 loss
+ ESI ionisation
Precursor ion 
selection
[M – NH3 + H+]
m/z = 151
Fragmentation
Product ion 
selection
m/z = 119
3-O-Methyldopa
M = 211
3-Methoxytyramine
M = 167
+ ESI ionisation
[M – COOH – NH2 + H+]
m/z = 151
[M + H+]
m/z = 212
Fig. 4. Ionisation and fragmentation to explain the product ion cross talk which results in over-estimation of 3MT concentration by 3-O-Methyldopa interference
when these are not chromatographically resolved. This is particularly significant in patients with renal insufficiency or those on L-dopa treatment for Parkinson's
disease. Adapted from [10].
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The α-adrenoceptor agonist Midodrine is a pro-drug to desglymi-
dodrine and used to treat orthostatic hypotension. It is hypothysesised
that if either midodrine or desglymidodrine co-elute with MA they
undergo in-source transformation to interfere in the MA transition [53].
β-Adrenoceptor blockers (e.g. atenolol, metoprolol, propranolol) as
well as the α- / β-blocker labetolol may cause FP plasma MA but with a
low frequency [52].
In Parkinson's disease, L-dopa / Levodopa is used as a prodrug for
dopamine which has potential for pharmaco-physiological and analy-
tical interference in PMet measurement. It can be metabolised to do-
pamine and thereby its O-methylated metabolite 3MT [54]. Moreover,
as previously discussed it can be metabolised to 3-O-Methyldopa with
potential for 3MT analytical interference [51]. Methyldopa may co-
elute with NMA in some methods [21].
Isoetharine and 3,4-methylenedioxyamphetamine (MDA) have been
shown to positively interfere with MA quantification whereas iso-
proterenol and 3,4-methylenedioxymethamphetamine (MDMA) posi-
tively interfere with NMA quantification [22]. Isoetharine and iso-
proterenol are betaadrenergic agonists whereas both MDA and MDMA
are recreational drugs. In all cases, structural similarity between the
interferant and metadrenalines are likely to cause interference by in-
source transformation or ionic cross talk [10].
4-Hydroxy-3-methoxymethamphetamine (HMMA), a metabolite of
MDMA, has also been shown to interfere in NMA measurement. It is
thought that in-source fragmentation (water loss from NMA and double
demethylation of HMMA) give the same precursor ion (m/z 166) and
product ion (m/z 134). Higher circulating levels of HMMA results in
over-estimation of NMA unless chromatographic separation is em-
ployed [55].
3.4. Diet
Overnight fasting is recommended prior to PMet sampling when
3MT is being measured [1,56]. This is because many foods contain L-
dopa, dopamine and other biogenic amines which can falsely increase
plasma 3MT concentrations. Catecholamine-rich foods include fruit
(e.g. bananas, pineapples), nuts (e.g. walnuts), potatoes, tomatoes,
beans, etc. [56].
Caffeine [57,58] and nicotine can increase plasma catecholamines
and, thus, some sources recommend avoiding them prior to testing
[59]. Coffee contains the catechol caffeic acid. Caffeic acid and its de-
rivative dihydrocaffeic acid can interfere in plasma catecholamine as-
says [58]. Moreover, these catechols can act as substrates for catechol
O-methyltransferase, thereby providing a mechanism for catecholamine
conversion to metadrenalines [59]. Coffee may also stimulate
adrenomedullary catecholamine release [57]. However, this does not
appear to have been studied using LC-MS/MS assays and one study
using radioimmunoassay showed that although NMA concentration was
increased significantly the changes were too small to confound inter-
pretation [60].
3.5. Renal function
PMets are less affected by impaired renal elimination that urine
metadrenalines [5]. The relatively mild effect of renal function makes
PMets more suitable for the diagnosis of pheochromocytoma in patients
with renal dysfunction [61], but renal function should still be con-
sidered when interpreting PMet results, particularly in patients on
dialysis. Studies have shown that plasma NMA and MA concentrations
are higher and increased above the ULRI in some patients with renal
insufficiency [61,62]. Activation of the sympathetic nervous system
(and, thus, increased plasma concentrations of catecholamines and
their metabolites) or decreased renal clearance of circulating O-me-
thylated metabolites are potential mechanisms for this increase
[61,63,64]. Activation of the sympathetic nervous system is thought to
be the most important factor since there is no strong inverse relation-
ship between PMets and creatinine clearance [61] and circulatory
clearance of PMets is relatively independent of renal function [61,65].
Some of these studies are based on electrochemical detection methods
and chromatographic interference from matrix factors may be con-
tributory, particularly in patients on dialysis [61].
Although renal dysfunction can lead to FP PMet results, the mag-
nitude of the elevations (up to 2-fold) are not usually in a range more
strongly suggestive of phaeochromocytoma [61]. This was not always
the case for MA in a study based on enzyme-linked immunosorbent
assays [62].
More recent studies based on LC-MS/MS methods have aimed at
deriving CKD-specific reference intervals for NMA, MA and 3MT to
account for the progressively higher PMet concentrations with more
advanced CKD [66]. This could not be achieved for 3MT due to
variability within the data set. CKD-stage specific reference intervals
were more important for NMA, whereas similar adjustments could be
made for all CKD stages for MA [66]. This strategy may help to decrease
FP results but their applicability to different sites with different
methods would need investigation.
3.6. Other factors
Other factors have been shown to affect PMet concentrations and,
thus, warrant consideration when interpreting biochemical test results.
Table 4
Summary of drugs that can cause pharmaco-physiological or analytical interference in LC-MS/MS methods for PMets i.e. false positives. Adapted from [5].
Interferent Cause of increase NMA MA 3MT References
Phenoxybenzamine Pharmaco-physiological Y [1,52]
Tricyclic (and other) antidepressants e.g. venlafaxine Pharmaco-physiological Y [1,52,81]
Monoamine oxidase (MAO)-inhibitors Pharmaco-physiological Y Y Y [1,10]
Sympathomimetics e.g. ephedrine, amphetamine Pharmaco-physiological Y Y [1,81]
Cocaine Pharmaco-physiological Y Y [1]
Midodrine Pharmaco-physiological Y [1,53]
β-Adrenoceptor blockers Pharmaco-physiological Y [52]
L-DOPA/Levodopa Pharmaco-physiological Y [54]
L-DOPA/Levodopa Analytical Y [51]
Isoetharine Analytical Y [22]
MDA Analytical Y [22]
Isoproterenol Analytical Y [22]
MDMA Analytical Y [22]
HMMA Analytical Y [55]
Note: Figures to appear in colour in online version only.
Abbreviations: HMMA - 4-Hydroxy-3-methoxymethamphetamine; LC- MS/MS - liquid chromatography tandem mass spectrometry; MA – metadrenaline; MDA - 3,4-
methylenedioxyamphetamine; MDMA - 3,4-methylenedioxymethamphetamine; NMA – normetadrenaline; PMets - plasma free metadrenalines; 3MT – 3-methox-
ytyramine.
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Other sympathetic or adrenal medullary stimuli can increase PMet
concentrations. Physiological stress, as seen in severe illness in in-
tensive care, can cause marked elevations [46,67,68]. To exclude FPs,
repeat testing is advocated after recovery from the illness [1]. Imaging
is required in an intensive care setting since the life-threatening,
stressful conditions make biochemical screening unreliable [43]. Other
co-morbidities causing PMet elevation include panic attacks and acute
anxiety [69–72], severe pain (e.g. during cardiac ischemia or hy-
poglycaemia) [43], heart failure [68,73], and obstructive sleep apnea
[74].
Two studies have found seasonal variation in PMets in patients
without PPGL, with higher NMA concentrations in the winter than
summer, with an associated increase in FP results in the winter [75,76].
Temperature and vasoconstriction/vasodilation effects on the sympa-
thetic nervous system were thought to contribute [75]. Notably, at least
one of these studies was based on an LC-ECD method [75]. Other stu-
dies have failed to find significant seasonal variation in more temperate
climates [77].
Some reports advocate adjusted reference intervals following uni-
lateral and bilateral adrenalectomy owing to lower MA and higher NMA
concentrations in these patients [78].
4. Conclusion
Evidence is accumulating which may result in PMet becoming the
preferred test for diagnosing PPGL. Moreover, increased availability
and benefits over other analytical methods like LC-ECD and IA are
causing LC-MS/MS to become the method of choice for PMet mea-
surement. This review explores the evidence-base supporting this, and
summarises published LC-MS/MS analytical methods for PMet analysis.
Key aspects of methods (including SPE extraction, HILIC chromato-
graphy, MRM MS-detection and standardisation) are discussed.
Common causes of analytical interference (e.g. ion suppression/en-
hancement, ionic cross talk, in source transformation and isobaric in-
terferences) are outlined to illustrate the importance of sample pur-
ification and chromatographic resolution. The importance of supine,
fasting sampling and Bayesian interpretation against supine, fasting
reference intervals are explained, as well as the importance of age-
specific reference intervals for NMA. Confounding factors like diet,
drugs, renal function and acute illness are explored, along with po-
tential strategies to address these (e.g. CKD-specific reference inter-
vals).
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